1. F. Roth, A.C. De La Fuente, J. L. Vella, A. Zoso, L. Inverardi and P. Serafini. “Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression.” Cancer Res. 2012 Mar 15;72(6):1373-83. Epub 2012 Jan 26
2. P. Daftarian, A.E. Kaifer, W. Li, B. B. Blomberg, D. Frasca, F. Roth, R. Chowdhury, E. A. Berg, J. B. Fishman, H. A. Al Sayegh, P. Blackwelder, L. Inverardi, V. L. Perez, V. Lemmon, and P. Serafini. “Peptide-conjugated PAMAM dendrimer as a universal platform for antigen presenting cell targeting and effective DNA-based vaccinations.” Cancer Res Dec 15;71(24):7452-62 (2011)
Time cited:1
3. Adeegbe D., P. Serafini, V. Bronte, A. Zoso, C. Ricordi and L. Inverardi. In vivo induction of myeloid suppressor cells and CD4+Foxp3+ T regulatory cells results in prolonged skin allograft survival in mice. Cell transplantation, Volume 20, Number 6, 2011 , pp. 941-954(14) (2011) Time cited: 5
4. Serafini P. PGE2-producing MDSC: a role in tumor progression?J Leukoc Biol. 2010 Nov;88(5):839-48. Time cited: 1
5. Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I.Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68, 5439-49 (2008). Times cited:90
6. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222, 162-79 (2008). Times cited: 171
7. Serafini P., K. Meckel, M. Kelso, K. A. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte and I. Borrello. Chronic phosphodiesterase-5 inhibition augments endogenous anti-tumor immunity by reducing myeloid suppressor cell function.J Exp Med. 2006203(12): 2691-702 Times cited:155
8. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Ugel S., Cingarlini S., Colombo MP., Basso G., Borrello I., Zanovello P., Bicciato S. Bronte V. Tumor induced a subset of inlammatory monocytes with a immunosuppressive activity on CD8+ cells. J Clin Invest. 2006 Oct 2; 116 (10):2777-2790
Times cited: 279
9. Serafini P., I. Borrello, V. Bronte. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Sem Cancer Biol. 16 (1): 53-65 FEB 2006 Times cited: 277
10. De Santo, C*., P. Serafini*, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M.P. Colombo, M. Iezzi, P. Musiani, P. Zanovello, V. Bronte. "Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination." Proc Natl Acad Sci U S A 102(11): 4185-90:2005 *These authors contributed equally to this work. Times cited: 92
11. Noonan, K., W. Matsui, P. Serafini, R.Carbley, G.Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, I. Borrello. "Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors." Cancer Res 65(5): 2026-34:2005 Times cited: 35
12. De Palma R. I. Marigo, F. Del Galdo, C. De Santo, P. Serafini, S. Cingarlini, T. Tuting, J. Lenz, G. Basso, G. Milan, P. Zanovello, Bronte, V. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res 64, 8068-76: 2004. Times cited: 17
13. Serafini, P., R. Carbley, K.A. Noonan, G.Tan, V. Bronte, I. Borrello. "High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells." Cancer Res 64(17): 6337-43: 2004 Times cited: 167
14. Bronte V., S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, O. Marin, P. Zanovello. Effective genetic vaccination with a widely shared tumor antigen requires CD40 stimulation during tumor rejection phase J. Immunol. 171, 6396-405:2003. Times cited: 17
15. Serafini P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, V. Bronte. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 53, 64-72: 2004 Times cited:187
16. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol., 24(6):302-6, 2003. Times cited: 167
17. V. Bronte*; P. Serafini*; C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D.M. Segal, C. Staib, M. Lowel, G. Sutter, M.P. Colombo, P. Zanovello IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol., 170: 270-278 , 2003. *These authors contributed equally to this work. Times cited: 165
18. Mazzoni, V. Bronte, E. Apolloni, P. Serafini, P. Zanovello, A. Visintin, J.H. Spitzer, J.A. Titus and D.M. Segal. Myeloid suppressor lines inhibit T cell responses by nitric oxide dependent and independent mechanisms. J. Immunol., 168:689-95, 2002. Times cited: 192
19. V. Bronte; P. Serafini; E. Apolloni; P. Zanovello. Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells. J. Immunother., 24:431-446, 2001. Times cited: 119
20. E. Apolloni, V. Bronte, A. Mazzoni, P. Serafini, A. Cabrelle, D.M. Segal, H.O. Young, and P. Zanovello. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lynphocytes. J. Immunol., 165:6723-30, 2000. Times cited: 76
21. Bronte, V., E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini, P. Zamboni, N.P. Restifo, and P. Zanovello. Identification of a common myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood, 96:3838-46, 2000. Times cited: 240
